Children’s healthcare rankings: Vermont named No. 1, Nevada last among states

Judging by 28 different metrics, Vermont offers the highest-quality and most cost-efficient care for children, according to a new study from personal finance website WalletHub, while Nevada struggles with limited access to care and poor oral health among those under the age of 18.

The rankings depended on metrics broken down into three categories: 1) kids’ health and access to care; 2) physical activity, nutrition and obesity; and 3) oral health. Each category contained several weighted indicators. For example, the children's health and access to care category included the uninsured rate among children in the state and the number of pediatricians and family doctors per capita.

Vermont had the highest percentage of children who have had preventive care visits with physicians and dentists in the prior year, along with leading in the “excellent or very good” oral health category. It was also ranked in the top five for most pediatricians per capita, lowest infant death rate and lowest number of uninsured children.

Nevada, on the other hand, had the highest uninsured rate among children under the age of 18 and the lowest percentage of children with medical and dental preventive care visits within the prior year.

You can read the full state-by-state rankings here.  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.